Preliminary data from second pivotal Phase III study
Preliminary data from second pivotal Phase III study showed Lucentis® maintained or improved vision in 95 percent of patients with age-related macular degeneration (AMD).
Like this story, share it with millions of investors on M3
Preliminary data from second pivotal Phase III study
Preliminary data from second pivotal Phase III study showed Lucentis® maintained or improved vision in 95 percent of patients with age-related macular degeneration (AMD).
Like this story, share it with millions of investors on M3
Preliminary data from second pivotal Phase III study
Preliminary data from second pivotal Phase III study showed Lucentis® maintained or improved vision in 95 percent of patients with age-related macular degeneration (AMD).
